Lighthouse Project (Triumeq)

What does Triumeq do?

Triumeq appears to be safe and well tolerated in patients with MND. It is currently used safely to treat people with HIV, which is a virus known as a retrovirus. Retroviruses are ancient viruses that have left their genetic material in our DNA during the process of human evolution. In some people, this old genetic material may become activated and play a role in the development of MND.

Lighthouse II

Results from earlier trials of Triumeq indicate that it may have a a positive effect on both clinical measurement and survival of people with ALS (amyotrophic lateral sclerosis), which is the most common form of MND. 

However, this was only a small study and the much larger international phase 3 Lighthouse II will determine if Triumeq improves both survival and clinical progression. Lighthouse II is a randomised, double-blind, placebo-controlled study. This means that trial participants will be randomly assigned to receive either Triumeq or a placebo. A placebo drug contains no active ingredients. 

How can I take part in this trial?

Trial sites and eligibility criteria are listed below. In order to take part in a clinical trial, you should first speak to your neurologist or MND Clinic. Triumeq is a single once-daily tablet that can taken either whole or crushed. 

Eligibility criteria 

1. Sporadic ALS diagnosed as probable, laboratory-supported probable or definite according to the Gold Coast criteria
2. Diagnosis <24 months from date of enrolment
3. Forced Vital Capacity (FVC) of at least 60% on baseline
4. Exclusion criteria:
   • dependence on mechanical ventilation at the time of screening
   • gastrostomy at the time of screening
   • absence of upper motor neuron signs

Want to know more?

For more information visit clinicaltrials.gov

For outcomes from earlier trials of Triumeq you can read a 2019 publication titled Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial